338 related articles for article (PubMed ID: 26708594)
1. Molecular Mechanisms of Bone Metastasis.
Weidle UH; Birzele F; Kollmorgen G; Rüger R
Cancer Genomics Proteomics; 2016; 13(1):1-12. PubMed ID: 26708594
[TBL] [Abstract][Full Text] [Related]
2. Dickkopf-1 as a mediator and novel target in malignant bone disease.
Rachner TD; Göbel A; Benad-Mehner P; Hofbauer LC; Rauner M
Cancer Lett; 2014 May; 346(2):172-7. PubMed ID: 24462802
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of tumor metastasis to the bone: challenges and opportunities.
Reddi AH; Roodman D; Freeman C; Mohla S
J Bone Miner Res; 2003 Feb; 18(2):190-4. PubMed ID: 12568395
[TBL] [Abstract][Full Text] [Related]
4. Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer.
Quayle L; Ottewell PD; Holen I
Curr Cancer Drug Targets; 2015; 15(6):469-80. PubMed ID: 25968899
[TBL] [Abstract][Full Text] [Related]
5. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.
Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A
FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966
[TBL] [Abstract][Full Text] [Related]
6. The bone microenvironment invigorates metastatic seeds for further dissemination.
Zhang W; Bado IL; Hu J; Wan YW; Wu L; Wang H; Gao Y; Jeong HH; Xu Z; Hao X; Lege BM; Al-Ouran R; Li L; Li J; Yu L; Singh S; Lo HC; Niu M; Liu J; Jiang W; Li Y; Wong STC; Cheng C; Liu Z; Zhang XH
Cell; 2021 Apr; 184(9):2471-2486.e20. PubMed ID: 33878291
[TBL] [Abstract][Full Text] [Related]
7. Local effects of malignancy on bone.
Brown SA; Clines GA; Guise TA
Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):436-41. PubMed ID: 17982348
[TBL] [Abstract][Full Text] [Related]
8. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
[TBL] [Abstract][Full Text] [Related]
9. Tumour but not stromal expression of β3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer.
Carter RZ; Micocci KC; Natoli A; Redvers RP; Paquet-Fifield S; Martin AC; Denoyer D; Ling X; Kim SH; Tomasin R; Selistre-de-Araújo H; Anderson RL; Pouliot N
J Pathol; 2015 Apr; 235(5):760-72. PubMed ID: 25430721
[TBL] [Abstract][Full Text] [Related]
10. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence.
Awolaran O; Brooks SA; Lavender V
Breast; 2016 Dec; 30():156-171. PubMed ID: 27750106
[TBL] [Abstract][Full Text] [Related]
12. Comparative role of acetylation along c-SRC/ETS1 signaling pathway in bone metastatic and invasive mammary cell phenotypes.
Bendinelli P; Maroni P; Matteucci E; Desiderio MA
Biochim Biophys Acta; 2011 Oct; 1813(10):1767-76. PubMed ID: 21741415
[TBL] [Abstract][Full Text] [Related]
13. Tumour dormancy in inflammatory microenvironment: A promising therapeutic strategy for cancer-related bone metastasis.
Hu W; Zhang L; Dong Y; Tian Z; Chen Y; Dong S
Cell Mol Life Sci; 2020 Dec; 77(24):5149-5169. PubMed ID: 32556373
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
15. The molecular signature of breast cancer metastasis to bone.
Bahrami T; Mokmeli S; Hossieni H; Pourpaknia R; Makani Z; Salmaninejad A; Estiar MA; Hossieni A; Farshbaf A
Anticancer Drugs; 2016 Oct; 27(9):824-31. PubMed ID: 27384592
[TBL] [Abstract][Full Text] [Related]
16. Bone metastases in breast cancer, prostate cancer and myeloma.
Paterson AH
Bone; 1987; 8 Suppl 1():S17-22. PubMed ID: 3318889
[TBL] [Abstract][Full Text] [Related]
17. Endocrine aspects of bone metastases.
Hofbauer LC; Rachner TD; Coleman RE; Jakob F
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):500-12. PubMed ID: 24880565
[TBL] [Abstract][Full Text] [Related]
18. The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.
Midavaine É; Côté J; Sarret P
Cancer Metastasis Rev; 2021 Jun; 40(2):427-445. PubMed ID: 33973098
[TBL] [Abstract][Full Text] [Related]
19. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
[TBL] [Abstract][Full Text] [Related]
20. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
